Joined you Jim on MCET .43 +.17 here: MultiCell Technologies Files Milestone Patent to Treat Cancer
Thursday September 28, 4:01 pm ET
Proprietary Technology Applies Company's Immune-Based Therapeutics to Target Malignant Tumors in Potential Multibillion-Dollar Markets
SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB: MCET - News), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced the filing of a milestone patent that provides a potential method for treating a range of malignant tumors using the Company's unique technologies to manipulate the immune system.
ADVERTISEMENT
MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide. The new patent filing broadens protection of MultiCell's intellectual property portfolio, and further expands the Company's potential therapeutic development targets to include cancer.
The patent filing, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
"The implications for this patent-pending technology are far-reaching and could someday help treat the millions of patients suffering from various cancers," said Dr. Stephen Chang, President and Chief Executive Officer of MultiCell. "We believe that this patent further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics."
The Company's technology platforms include TLR and T-cell targeting to modulate both the innate and adaptive immune systems, thus enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting.
MultiCell's new patent provides a method for treatment of a tumor after clinical diagnosis. The method involves the loading of an antigen presenting cell with at least one tumor associated T-cell epitope attached to an IgG backbone to form an Ig-peptide molecule followed by administration of the Ig-peptide molecule in vivo in conjunction with MultiCell's dsRNA TLR therapeutic.
MultiCell has a therapeutic pipeline with drug candidates already in various advanced stages of human clinical trials. These therapies include:
MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.
MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models.
MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.
MCT-465 for the treatment of virus infection. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit multicelltech.com. For investor information about MultiCell, please visit trilogy-capital.com. For current stock price quotes and news, visit trilogy-capital.com. To view the Company's Investor Fact Sheet, visit trilogy-capital.com. To listen to an archived investor conference call, visit trilogy-capital.com.
Contact:
MultiCell Technologies, Inc.
Dr. Stephen Chang
MCETInvestor@MultiCelltech.com
or
Trilogy Capital Partners (Financial Communications)
Paul Karon, 800-592-6067
paul@trilogy-capital.com
--------------------------------------------------------------------------------
Source: MultiCell Technologies, Inc. |
